Putative role of circulating human papillomavirus DNA in the development of primary squamous cell carcinoma of the middle rectum: A case report by Ambrosio M.R. et al.
CASE REPORT
published: 21 February 2019
doi: 10.3389/fonc.2019.00093
Frontiers in Oncology | www.frontiersin.org 1 February 2019 | Volume 9 | Article 93
Edited by:
Konrad Steinestel,
Bundeswehrkrankenhaus Ulm,
Germany
Reviewed by:
Guglielmina Nadia Ranzani,
University of Pavia, Italy
Paolo Giorgi Rossi,
Azienda Sanitaria Unità Locale di
Reggio Emilia, Italy
*Correspondence:
Stefano Lazzi
lazzi2@unisi.it
Monica Cricca
monica.cricca3@unibo.it
Specialty section:
This article was submitted to
Gastrointestinal Cancers,
a section of the journal
Frontiers in Oncology
Received: 19 November 2018
Accepted: 01 February 2019
Published: 21 February 2019
Citation:
Ambrosio MR, Vernillo R, De
Carolis S, Carducci A, Mundo L,
Ginori A, Rocca BJ, Nardone V,
Lucenti Fei A, Carfagno T, Lazzi S,
Cricca M and Tosi P (2019) Putative
Role of Circulating Human
Papillomavirus DNA in the
Development of Primary Squamous
Cell Carcinoma of the Middle Rectum:
A Case Report. Front. Oncol. 9:93.
doi: 10.3389/fonc.2019.00093
Putative Role of Circulating Human
Papillomavirus DNA in the
Development of Primary Squamous
Cell Carcinoma of the Middle
Rectum: A Case Report
Maria Raffaella Ambrosio 1, Remo Vernillo 2, Sabrina De Carolis 3,4, Antonietta Carducci 1,
Lucia Mundo 1, Alessandro Ginori 5, Bruno Jim Rocca 5, Valerio Nardone 6,
Alessandra Lucenti Fei 2, Tommaso Carfagno 6, Stefano Lazzi 1*, Monica Cricca 4* and
Piero Tosi 6
1Department of Medical Biotechnology, University of Siena, Siena, Italy, 2Department of Medical Sciences, Surgery and
Neuroscience, University of Siena, Siena, Italy, 3Center of Applied Biomedical Research (CRBA), S. Orsola-Malpighi Hospital,
Bologna, Italy, 4Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy,
5 Pathology Unit, Ospedale Civico di Carrara, Carrara, Italy, 6 Retired, Siena, Italy
Here we present the case of a patient affected by rectal squamous cell carcinoma in
which we demonstrated the presence of Human Papillomavirus (HPV) by a variety of
techniques. Collectively, the virus was detected not only in the tumor but also in some
regional lymph nodes and in non-neoplastic mucosa of the upper tract of large bowel.
By contrast, it was not identifiable in its common sites of entry, namely oral and ano-
genital region. We also found HPV DNA in the plasma-derived exosome. Next, by in vitro
studies, we confirmed the capability of HPV DNA-positive exosomes, isolated from the
supernatant of a HPV DNA positive cell line (CaSki), to transfer its DNA to human colon
cancer and normal cell lines. In the stroma nearby the tumor mass we were able to
demonstrate the presence of virus DNA in the stromal compartment, supporting its
potential to be transferred from epithelial cells to the stromal ones. Thus, this case report
favors the notion that human papillomavirus DNA can be vehiculated by exosomes in
the blood of neoplastic patients and that it can be transferred, at least in vitro, to normal
and neoplastic cells. Furthermore, we showed the presence of viral DNA and RNA in
pluripotent stem cells of non-tumor tissue, suggesting that after viral integration (as
demonstrated by p16 and RNA in situ hybridization positivity), stem cells might have
been activated into cancer stem cells inducing neoplastic transformation of normal tissue
through the inactivation of p53, p21, and Rb. It is conceivable that the virus has elicited
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its oncogenic effect in this specific site and not elsewhere, despite its wide
anatomical distribution in the patient, for a local condition of immune suppression,
as demonstrated by the increase of T-regulatory (CD4/CD25/FOXP3 positive) and T-
exhausted (CD8/PD-1positive) lymphocytes and the M2 polarization (high CD163/CD68
ratio) of macrophages in the neoplastic microenvironment. It is noteworthy that our
findings depicted a static picture of a long-lasting dynamic process that might evolve
in the development of tumors in other anatomical sites.
Keywords: circulating HPV, immune evasion, exosomes, middle rectum, cancer
INTRODUCTION
Human papillomavirus (HPV) DNA has been detected in
a variety of cancer, including colorectal cancer (CRC) (1–
4). Through the integration of viral DNA into the human
genome, expression of oncoproteins, and inactivation of tumor
suppression genes, HPV damages cell proliferation in its site of
infection, inducing oncogenesis (2). Recently, HPV DNA has
been found as circulating DNA in the serum of patients with
HPV-associated invasive carcinoma (5) and its presence has
been considered as a useful biomarker for disease recurrence
(6). Tumor-derived exosomes and extracellular vesicles are
garnering increasing attention because of their ability to
transfer bioactive molecules (mRNAs, microRNAs, DNA, and
proteins) between neighboring cancerous or normal cells,
and to contribute to human cancer progression. Moreover,
exosomes and extracellular vesicles have been implicated in
HPV transmission and carcinogenesis (7), and the presence
of HPV DNA in the serum derived extracellular vesicles
(EVs) of patients with breast diseases has been recently
reported (8).
While there is a strong association between HPV and
squamous cell carcinoma of some sites (e.g., genitals, anus, and
head and neck region), the putative role of the virus in colorectal
carcinogenesis still remains controversial (9). Detection of HPV
in colonic tissue has led to a wide range of studies, analyzing the
possibility of a casual or pathogenetic association between HPV
and CRC. However, these studies applied different techniques
for the detection of the virus, with discordant findings and
inconsistencies in result reproducibility (10). In fact, it is very
difficult that a causative role of HPV in a cancer can be
explained only studying the molecular mechanisms. Since it
is a very common virus, its presence can be occasional and
the behave of the virus opportunistic. The proof of causation
needs both studies on the molecular mechanisms and studies
establishing that the probability a tumor occurs is higher when
the HPV is present that when it is not, i.e., case control and
cohort studies.
CRC is the third most common cause of cancer-related
death in the world (11). Among its histotypes, pure squamous
cell cancer (SCC) is very unusual, ranging from 0.1 to 0.25
per 1,000 CRC; its diagnosis is based on the restrictive criteria
given by Williams et al. (12). Risk factors include proctitis, past
history of radiotherapy to pelvic region, Schistosomiasis
and Amoebiasis infection (13). The exact pathogenic
mechanism remains speculative and several theories have been
proposed (14, 15).
Here we present the case of a patient affected by rectal SCC in
which we demonstrated HPV by immunohistochemistry,
polymerase chain reaction (PCR), chromogenic in situ
hybridization (CISH), and RNA in situ hybridization (ISH)
for E6/E7 viral oncogenes mRNA in neoplastic and non-
neoplastic tissues, including lymph nodes and sites far from
the rectum. We also found HPV DNA in the plasma-derived
from the patient, and by in vitro studies, we confirmed the
capability of HPV DNA positive exosomes to transfer its DNA to
recipient cells.
BACKGROUND
Clinical Presentation
A 53 years-old caucasian man presented to our hospital
complaining of sub-occlusive syndrome that lasted for 1
week. Family and medical history was unremarkable. Physical
examination including digital rectal examination was negative.
Colonoscopy showed a 5.0 × 4.5 × 4 cm lesion, 10 cm from
the anal verge. The lesion was ulcerated and bleeding, it
narrows the lumen and renders difficult to be overcome.
Computed tomography (CT)-scan identified a heteroplastic and
locally advanced lesion with enlarged lymph nodes (the greatest
measuring 13mm in maximum diameter) along the sigmoid
chain. Neither pulmonary, hepatic, splenic localizations nor
pleural or peritoneal effusions were identified. An anterior
resection of the rectum and regional lymph nodes was performed
without colostomy. Postoperatively, the patient underwent
adjuvant radiotherapy of 45Gy delivered to the pelvis in 25
fractions over 5 weeks. To date, after 60 months follow-up, the
patient is alive and in good conditions, with no evidence of
recurrence. Ethics approval for this study was obtained from the
Institutional Review Board at the University of Siena (Italy) and
written informed consent was obtained from the patient for the
publication of this case report and any potentially-identifying
information/images.
Materials and Methods
Tables 1–3 summarize the main techniques applied in the
different samples.
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TABLE 2 | HPV DNA detection with different primer set.
Primer set Target Forward (5′–3′) Reverse (5′–3′) Length NT position
E1 HPV16 ATCGTAATWSAGCCWCCAAAATT TTATCAWATGCCCAYTGTACCAT 188 1,777–1,964
E6 HPV16 AAAGCCACTGTGTCCTGAAGA CTGGGTTTCTCTACGTGTTCT- 130 424–553
L1 HPV16 TTTGTTACTGTGGTAGATACTAC GAAAAATAAACTGTAAATCATATTC 140 6,625–6,768
The nucleotide position (NT) was assessed on the reference sequence NC_001526 (Human Papillomavirus 16 type).
TABLE 3 | Immunohistochemical analysis.
Target Clone Source Retrieval/dilution
p63 4A4 Ventana (Roche) RTU
CK20 SP33 Ventana (Roche) RTU
CK5/6 D516B4 Ventana (Roche) RTU
CK7 SP52 Ventana (Roche) RTU
p16 P16 Ventana (Roche) RTU
Synaptophisin MRQ40 Ventana (Roche) RTU
Chromogranin LK2H10 Ventana (Roche) RTU
OCT3/4 MRQ/10 Ventana (Roche) RTU
p53 DO/7 Ventana (Roche) RTU
p21 EPR18021 Abcam 1:150
Rb Rb1 1F8 Abcam 1:200
PDL-1 SP263 Ventana (Roche) RTU
PDL-2 366C-9E-5 Biox Cell RTU
PD-1 NAT105 Ventana (Roche) RTU
CD25 IL2R.1 ThermoFisher 1:200
CD4 SP35 Ventana (Roche) RTU
CD8 SP57 Ventana (Roche) RTU
FOXP3 SP97 Spring 1:50
CD68 KP/1 Ventana (Roche) RTU
CD163 CD163 Leica Biosystem 1:200
RTU, ready to use; Ventana- Roche, Mannheim (Germany); Abcam, Cambridge
(United Kingdom); Biox Cell, West Lebanon (NH, USA); ThermoFisher, Rockford (USA);
Spring, Pleasanton (USA); Leica Biosystem, New Castle (United Kingdom).
RESULTS
Pathological Characterization
Grossly, an exophytic ulcerative mass with predominantly
intraluminal growth and narrowing of the lumen was identified.
The lesionmeasured 5.0× 4.0× 3.5 cm and extended throughout
the muscular layer but without mesorectal involvement in the
extraperitoneal tract of the specimen. On cut section, the
mass had a relatively homogeneous appearance with focal
areas of necrosis and hemorrhages. Microscopic examination
demonstrated a moderately differentiated squamous cell
carcinoma with basaloid features and koilocyte-like cells
(Figure 1A, inset). Neither perineural nor lymphovascular
invasion was present. Surgical margins as well as the regional
lymph nodes examined showed no cancer infiltration. The final
diagnosis according to Williams et al. criteria was G2 (12),
pT3N0Mx, IIA (TNM 2017) primary squamous cell carcinoma
of the rectum. By immunohistochemistry (IHC), the neoplastic
cells were p63 and CK20 positive, and CK5/6 and CK7 negative,
thus ruling out a possible rectal extension from an occult
anal neoplasm.
HPV Detection and Oncogenicity
The atypical localization of a SCC in the rectum and the
detection of koilocyte-like differentiated cells within the tumor
were indicators of the possible presence of HPV. Therefore,
we searched the virus in the tumor mass, in its margins, in
tumor-free normal rectal mucosa proximal to the tumor and in
the lymph nodes by IHC for p16, PCR assays, CISH for HPV
nucleic acids (ZytoFast PLUS CISH Implementation Kit HRP-
DAB and ZytoFast HPV type 16/18 Probe, ZytoVision, Bio-
Optica, Milan, Italy) and RNA ISH for E6/E7 mRNA transcripts
(RNAscope R©2.5 HD Assay- RED, probe HPV 16, Acdbio, Milan,
Italy) (Table 1).
By IHC for p16, a useful surrogate biomarker of HPV
integration and E7 over-expression (16), strong positivity was
detected only in the neoplastic cells (Figure 1B) and in scattered
large cells in the germinal center and in the subcapsular sinus
of some lymph nodes (Figure 1C). The margins and tumor-free
normal rectal mucosa did not show p16 expression.
PCR assays for HPV DNA detection were performed by
MY09/11 (17) primer pool, able to amplify about forty mucosal
HPV DNAs, then with different primer set, including E1, E6,
and L1 primers (Table 2). HPV DNA was found in the tumor,
surgical margins, tumor free normal rectal mucosa proximal
to the neoplastic cells and in the largest dissected lymph
node (Figure 2A, Table 1). Sequence analysis of PCR products
sustained the specificity of the PCR results and identified HPV
16 genotype (Figure 2B). The presence of HPV DNA in the
tumor, surgical margins and tumor free normal rectal mucosa
proximal to the neoplastic cells was also confirmed by CISH
(Figures 3A,B) and RNAscope assay (Figures 3C,D, D inset,
Table 1). As far as CISH and RNA scope assays is concerned,
intriguingly, we detected two different pattern of expression
in tumor and cancer-free samples. In the neoplastic tissue we
observed a “punctated” pattern with distinct multiple dot-like
intranuclear signals by CISH (Figure 3A) and strong red dot-
like signals by RNAscope (Figure 3C), which are typical of viral
integration. Whereas, in the non-neoplastic tissue we detected a
“diffuse” black pattern by CISH (Figure 3B) and only few weak
red signals by RNAscope (Figure 3D, D inset), which are typical
of episomal DNA (18, 19). Therefore, the virus was integrated
only in neoplastic cells.
Interestingly, in the non-neoplastic tissue, the HPV16
positive signals by CISH and RNAscope were localized
within the gland crypts (Figures 3B,D). To better characterize
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FIGURE 1 | Pathological characterization. The morphological and immunohistochemical evaluation of the surgical specimen showed the presence of a squamous cell
carcinoma with basaloid features and koilocyte-like cells (arrow) (A, inset), and p16 expression (B); the largest lymph node examined demonstrated p16 positivity in
scattered large cells of the germinal center and the subcapsular sinus (arrow) (C). A, (A)-inset: haematoxylin and eosin (H&E); B,C: p16 staining. Original magnification
(O.M.): A, 2.5x; (A)-inset, (B,C) 20x.
the nature of these cells (endocrine vs. stem-cell), double
staining for HPV (by CISH) and chromogranin, synaptophyn,
OCT3/4 (by IHC) was performed. The infected cells were
OCT3/4-positive and chromogranin/synaptophyn-negative, thus
presumably representing stem-cells (Figure 3B, B inset, Table 3).
The expression of tumor suppressor genes p53, p21, and Rb
was absent in the tumor mass and in adjacent tissues, thus
supporting the view that HPV was oncogenic in our case.
At the first follow-up, multiple biopsies of caecum/ascending,
and descending colon, as well as oral swab and anal and uretral
scrapes were collected and analyzed for HPV infection (Table 1).
HPV was no detected in the oral and ano-genital regions; we
demonstrated the presence of HPV DNA in all of the biopsies
of right and left colon by PCR (Figure 2A), whereas CISH and
RNAscope assays were negative, thus confirming that the virus
was integrated only in the neoplastic cells.
HPV Circulation
We searched for presence of HPV DNA in the plasma-derived
exosomes of the patient (Figure 4A). Exosomes were isolated
from plasma specimens by CD9 immunobeads isolation kit
(HansaBioMed Life Sciences Ltd. Cod. HBM-BOLC-CC/20-1)
according to manufacturer’s instruction. Prior to DNA extraction
of the exosomes content, we performed a DNAseI digestion to
remove contaminant DNA. We searched for HPV DNA by using
PCR assay (MY09/11 and E6 primers) and we found the presence
of HPV 16 DNA, as resulted by sequence alignment of the PCR
product (Figure 4B). Thus, we tested the hypothesis that HPV
DNA could be transferred to recipient cells by exposing cells to
HPVDNApositive exosomes. HPVDNApositive exosomes were
obtained from the supernatant of an HPV DNA positive cell line,
the Caski cell line, which was established from a metastasis in the
small bowel mesentery and contains HPV16 DNA integrated into
the genome. We confirmed in vitro the capability of HPV DNA
positive exosomes to transfer their content to HPVDNAnegative
cells, such as neoplastic and normal colon cell lines, HCT116
and NCM460, respectively, by digital PCR and conventional PCR
(Figures 4C,D). The amplification reaction was performed by
Digital PCR, with TaqMan assay (Vi03453396_s1, Invitrogen,
Milan, Italy) for HPV 16 E1 gene amplification and conventional
PCR with E6 primers (Table 1). Interestingly, by CISH we
found the presence of HPV DNA in the stromal cells
(fibroblasts and endothelial cells) nearby the neoplastic cells,
suggesting an horizontal transfer of viral DNA from cancer
cells (Figure 4E).
Microenvironment Characterization
More recently, local immune evasion has been involved in
the development of gut cancer (20–22). Thus, we studied
the neoplastic and non-neoplastic microenvironment of our
patient by single and multiple IHC stainings. Interestingly, we
demonstrated an increase of PDL-1 and PDL-2 expression
in neoplastic cells coupled by PD-1 positivity of the
reactive cells in the background (Figures 5A–C). This
finding reflects a neoplastic environment with a reduced
immune surveillance; in fact, the PD-1/PD-L1 molecular
pathway can act to fine-tune the cellular fate of tumor-
infiltrating T-cells. Interestingly, we detected an increase
of T-regulatory cells (CD25/CD4/FOXP-3 positive) and a
number of exhausted T-lymphocytes (CD8/PD-1 positive) in
the neoplastic microenvironment when compared to non-
neoplastic mucosa (Figures 5D,E). In addition, polarization
of tumor-associated macrophages to an M2 phenotype was
observed. In fact, the CD163/CD68 ratio was significantly
higher in tumor than in non-neoplastic tissue (Figures 5F,G)
(23) (Table 3).
DISCUSSION
Previous studies onHPV in CRC are conflicting (24).While some
of them report HPV DNA in 31 −53% of CRC, others identified
no HPV DNA (25, 26). Moreover, some Authors recognized
transcriptional activity of the HPV E6/E7 oncogenes critical to
HPV’s role in carcinogenesis, while others not (27–29). In our
case study, HPV nucleic acids were detected in the neoplastic
cells and in the normal crypts of the margins, non-neoplastic
mucosa, random biopsies of the left and right colon as well as
in some lymph nodes. It is known that inactivation of the E2
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FIGURE 2 | Human Papillomavirus polimerase chain reaction identification and typing. The presence of HPV 16 DNA was confirmed by HPV 16 genotype specific
primer pair 5′- AAAGCCACTGTGTCCTGAAGA-3′ and 5′-CTGGGTTTCTCTACGTGTTCT-3′ able to amplify a 130 bps long fragment (424–553 nt, ref Seq Human
Papillomavirus 16 type NC_001526). B, Blank, (1) Tumor mass, (2) Proximal margin, (3) Distal margin, (4) Lymph node, (5) Tumor-free mucosa of the surgical
specimen, (6) Descending colon biopsies, (7) Caecum/ascending colon biopsies, (8) HPV DNA negative cervical cytological specimen, (9) HPV DNA positive cervical
cytological specimen, M, Molecular weight marker (A). HPV 16 was present in the tumor mass as it is evident by the sequence alignment of the 460 bps L1 sequence
obtained by MY11/09 PCR primers (B). HPV, Human Papillomavirus.
gene through genomic integration promotes the expression of
the E6 and E7 oncoproteins, which induce a loss of cell-cycle
control by antagonizing the function of p53 and Rb, respectively
(30). The resulting degradation of p53 and Rb mediated by these
oncoproteins facilitates viral DNA proliferation within the host
and leads to neoplasia (31). Accordingly, in our case we detected
viral integration by p16 IHC, CISH, and RNA ISH for E6/E7
mRNA only in neoplastic cells coupled with no expression of p53,
p21, and Rb. This supports the view that HPV might be involved
in tumorigenesis, rather than simply representing a fortuitous
or chance passenger through tissues. Interestingly, we did not
find the virus in its physiologic ports of entry (i.e., oral and ano-
genital region). This, along with the wide anatomical distribution
of HPV in our samples implies that the infection was not just
the result of a retrograde viral transmission from the ano-genital
area. However, we cannot exclude that a past productive infection
could has been the primary source of the widespread infection in
our patient.
Previous studies on cervical, oropharingeal, and breast
diseases demonstrated the presence of circulating HPV DNA
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FIGURE 3 | Human Papillomavirus detection and integration. In the neoplastic cells multiple black signals were shown by CISH with a “punctated” pattern
characterized by multiple distinct dot-like intranuclear signals indicating viral integration (A); the normal mucosa of the resected specimen demonstrated scattered
cells with HPV infection in a “diffuse” pattern with only few completely black stained nuclei corresponding to the episomal status of the virus (B). RNAscope assay
detected E6 and E7 transcripts in the neoplastic (C) and normal mucosa cells of the surgical specimen (D, D inset) as multiple, strong red dot-like signals in the tumor
and only few weak red signals in the cancer-free mucosa, corresponding the first pattern to viral integration and the second one to episomal infection. HPV-infected
cells OCT3/4-positive (B inset). (A,B) CISH; (C,D) RNAscope; (A,C) original magnification (O.M.) 20x; (B,D) O.M. 40x; (B,D) inset, O.M. 63x. CISH, chromogenic in
situ hybridization; HPV, Human Papillomavirus.
in the blood of affected patients (8, 32–35). Accordingly, we
searched HPVDNA also in the blood of our patient. Intriguingly,
it was present in the CD9-positive fraction of the plasma,
namely the exosomes fraction. Then, we demonstrated by in
vitro studies that HPV DNA positive exosomes are capable to
transfer the viral nucleic acids to HPV DNA negative cells,
such as normal and transformed colon cell lines. In vivo, we
observed a horizontal transfer of HPV DNA by a cell to cell
communication mechanism to stromal cells (endothelial cells
and fibroblasts) as well as at distant sites (ascending/descending
colon). It is reasonable that HPV penetrated in the host by one
of the known site of entry. Following, the virus disappeared
from the original site thanks to clearing mechanisms (that are
highly active during the early phase of HPV infection) and
it was no more detectable there (2). HPV entered the blood
circulation via exosomes with shedding of nucleic acids in target
tissues (7–16). It is conceivable that the virus has elicited its
oncogenic effect (as demonstrated by the lack of p53, p21, and
Rb expression by IHC) specifically in the middle rectum for
a temporary condition of immune evasion (36) characterized
by up-regulation of T-regulatory and T-exhausted lymphocytes
and a polarization of tumor-associated macrophages with a
switching from M1 to M2 (17–19, 37) as demonstrated by IHC.
Moreover, we showed high expression of PDL-1 and PDL-2 by
neoplastic cells and strong positivity of the reactive background
to PD-1. It is also possible that the virus by itself induces
an immunomodulation as previously demonstrated for other
viruses (37, 38). Notably, we identified the reservoir of HPV
in non-neoplastic epithelial cells within the crypts of colonic
normal mucosa adjacent to the neoplastic mucosa and we
demonstrated that these cells were stem-cells, which are known
to be susceptible to transformation by HPV 16 (39, 40). It can
be argued that following inflammatory response to a number
of stimuli (also including dysbiosis) (41), non-cancer stem cells
may be activated into cancer stem cells, sustaining a feed-
forward circuit of self-renewal, proliferation, differentiation and
neoplastic transformation in a condition of immune evasion, as
previously demonstrated (40, 42–44). Due to the pluripotency
of stem-cells, a squamous cell carcinoma may arise also in
colorectal mucosa in the absence of anymetaplastic changes, as in
our case.
CONCLUDING REMARKS
Although important studies have been made for the
understanding of HPV tumorigenicity in non-genital cancers,
significant questions still remain. Our case-study seems to
highlight the direct relationship of HPV with the pathogenesis
of a squamous cell CRC; however, further studies including case
control and cohort studies are necessary to evidence the causal
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FIGURE 4 | Human papillomavirus circulation. Electrophoresis showed the amplified HPV DNA obtained from plasma and Caski cells supernatant-derived exosomes.
B, Blank; (1) Plasma-derived exosomes; (2) Caski cells; (3) Positive control (cervical HPV DNA positive cytological samples); M, Marker. The PCR assay was performed
with MY11/09 primers (A). Nucleotide blast of HPV DNA amplified product obtained from plasma-derived exosomes by MY11/09 primers (B). HCT116 and NCM460
cell lines were exposed to CasKi supernatant derived exosomes and analyzed by Digital PCR (QuantStudio® 3D Digital PCR System, Life Technologies) to determine
the capability of exosomes to transfer viral genetic material to recipient cells. Caski cell line was established from a metastasis in the small bowel mesentery and
contains HPV16 DNA integrated into the genome. The reaction was performed using TaqMan Assay specific for HPV 16 E1 (Vi03453396_s1, Invitrogen, Milan, Italy).
After 6 h of exposure the load of HPV DNA was greater than at 20 h in the normal human colon epithelial cell line (NCM460). In the human colon cancer cell line
(HCT116) we report an HPV DNA burst at 6 h and a rapid decay, indeed it was absent at 20 h post exposure. (1) HCT116 at 3 h; (2) HCT116 at 6 h; (3) HCT116 at
20 h; (4) NCM460 at 3 h; (5) NCM460 at 6 h; (6) NCM4 60 at 20 h (C). The specimens illustrated in (C) were also amplified by conventional PCR with E6 HPV 16
specific primer pair showing concordant results with Digital PCR. B, Blank, (1) not exposed HCT116; (2) HCT116 at 3 h; (3) HCT116 at 6 h; (4) HCT116 at 20 h; (5) not
exposed NCM460; (6) NCM460 at 3 h; (7) NCM460 at 6 h; (8) NCM460 at 20 h; (9) blank; (10) HPV DNA negative cervical specimen; (11) HPV DNA positive cervical
specimen (D). The neoplastic and the neighbor cells demonstrated HPV DNA in the endothelial cells (red arrow) and in the fibroblasts (black arrow) by both CISH
(brown chromogen) (E) and p16 IHC (E, inset). E, (E)-inset, original magnification 20x.
link between HPV infection and colon cancer. The presence
of HPV DNA positive plasma-derived exosomes in our patient
shed important light on poorly understood mechanisms of
HPV DNA horizontal transfer and on unconventional route
of HPV spreading and carcinogenesis. It is noteworthy that
HPV-induced cancerogenesis has a long-lasting history and
our findings depicted only a static picture of a dynamic process
for which we cannot exclude the development of cancers in
other anatomic sites of the patient after viral spreading and
DNA integration.
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FIGURE 5 | Microenvironment characterization. An increase of PDL-1 and PDL-2 expression in neoplastic cells was observed (A,B) whereas the reactive background
showed a higher percentage of PD-1 positive elements (C). The tumor infiltrating lymphocytes were represented mainly by CD8/PD-1 positive T-cells (D) which were
absent in normal mucosa (E). An increase of CD163/CD68-positive macrophages ratio was detected in the neoplastic component (F) as compared to the normal one
(G). (A) PDL-1 staining; (B) PDL-2 staining; (C) PD-1 staining; (D,E) CD8/PD-1 double staining (CD8 brown, PD-1 red); (F,G) CD163/CD68 double staining (CD163
brown, CD68 red). (A–G), original magnification 20x.
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